PHARMACEUTICAL HOL DEP RECEIPTS REP 20 PHARM I (AMEX:PPH)
Exchange Traded Funds
- Quote
- Commentary
- Scorecard
- Historical Prices
- Chart
- Stats
- Ratios
- Earnings/Growth Rates
- Statements
- SEC Filings
Recs
Pharmaceuticals should outperform due to low P/E.
Recs
At a glance this funds concentrated holdings seem to be good companies trading inexpensively. I am not a fan of most pharma companies as I have difficulties evaluating their pipeline and drug approvals (or lack thereof) have a huge determination of value. This distributes that risk. Thanks to Morningstar for the fund.
Recs
Betting to outperform the 500 this leg down.
Recs
Well I am tapped out of cash unless I go margin.. buying in at the open assuming we open higher tomorrow.... also need to take profits on previous positions on any sustained rally assuming I'm actually up... yikes
I hate agreeing with Cramer, but I have been waiting for a long time for sector rotation... i believe that rotation is going into healthcare... Obama is a wild card, but this and many of the green thumbs i made tonight are international companies... although the PPH is a basket of pharma stocks and will perform average vs. trying to pick individual pharma stocks my reasoning is as follows
1) the market is too volatile for even me to buy individual stocks so I am buying a basket of stocks in an industry going forward in the form of an ETF... see my recent KOL picks and ITB
2) pharma stocks can swing big on one drug blowing up or making it over the goal line... i don't want to take that gamble
3) i don't understand the industry enough to make a smart choice
so really this is a bet that we rotate into big pharma without taking substantial risk
it should be noted that healthcare stocks have done squat for years.. and I mean YEARS......... this terrible market with a lot of pharma trading at a PEG of 1 may be the entry point we are looking for... commodities have run forever, and most people don't have the stomach or believe to invest in financials, builders, etc... I'm not sold on tech either
4 of the top 23 industries are in healthcare (192 industries in all) and I haven't seen healthcare/drugs show this much money coming into the sector in a long time..
Watch Pharma closely once a new president is elected and his policies are better known......
Poor people smoking crack, eating at mcdonalds, sitting in front of the TV all benefit the drug companies unless Obama intends to force pharma to give this stuff away to the poor (picture the bread scene at the colliseum in the movie Gladiator)...
Obama scores a 9 on the stupidity index, so this position might not make it past November let alone 2 years
Recs
Big pharma across the board.
Recs
Great industry that is undervalued -
Recs
Stock is a good but sell at $30.00
Recs
Pharmaceutical sector enjoys one of the widest margins and expectation of increase in approval of new molecular entities in 2007 makes it a bright spot. With many blockbuster drugs set to loose patents protection in the coming years the pharmaceuticals sector has huge opportunities for generic and specialty segment.
With market cap of $1.92 billion Pharmaceutical HOLDRS represents companies that are involved in various segments of the pharmaceutical industry. The individual components of the fund are large cap with a blend of growth and value stocks. Historical returns of the fund are not very impressive with returns of 7.58% in the previous year. However the current valuations look attractive trading at a price to earnings multiple hovering around 17.
Johnson & Johnson though faced some challenges looks good being market leader in its respective segment and with solid research pipeline and expects to file at least 10 drug approvals. Pfizer looks solid with 14 out of the 25 best selling medicines in its kitty and has more than 150 drugs in the pipeline. Merck is emerging victorious out of the recently concluded Vioxx trials and Pfizer looks good with its pipeline of oncology related drugs and recently launched Exubera being a huge success.
Moreover the general character of the stocks has to been to pay high dividends concentrating more on product flow and cost stream lining measures. Companies with generic pipeline would benefit the most from the new Medicare Drug plan and the first to file would enjoy 180 days of marketing exclusivity. In the recent time companies benefit from the cost savings and synergies arising out of mergers and acquisitions that has helped then post huge profits. With signs of economy slowing the recession resistant pharmaceutical ETF is a good pick.
RSS Headlines
Fool UK
- Show Me:
-
Outperform
-
Underperform
-
All
- Sort by:
-
Author
-
Recs
-
Date
-
Member Rating
-
Results 1 - 8 of 8